Article details the groundbreaking decision and possible implications for Alzheimer’s patients
SAN DIEGO, Feb. 15, 2017 — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded Cannabis Company in the United States, subsidiary HempMeds® Brasil was featured in a Veja.com news article discussing that ANVISA permitted the usage of the company’s hemp oil product, Real Scientific Hemp Oil™ (RSHO) for patients suffering from the debilitating effects of Alzheimer’s disease.
Per data by the World Alzheimer 2016 Report, about 46.8 million people in the world have the disease and that number is expected to increase to 131.5 million by 2050.
“The recent article by Veja really highlights the vital need for our products in the lives of those suffering from conditions like Alzheimer’s Disease,” said Medical Marijuana Inc. CEO, Dr. Stuart Titus. “Slowly but surely, because of wide reaching articles like this, the world is beginning to realize the benefits of CBD hemp oil products on diseases and disabilities that are oftentimes uncured. We applaud the nation of Brazil, and their health authority in taking proactive measures to see that our products get to those that need it most. Our company looks forward to continue in our efforts with Brazil, and around the world to ensure that those who continue to suffer are brought the relief they so desperately deserve.”
“Recent studies on Alzheimer’s from Stanford University researchers shows that Alzheimer’s is caused by an Endogenous Cannabinoid Deficiency – and this, along with the wonderful work from Dr. David Schubert of the San Diego based Salk Institute, bodes quite well for the future of cannabinoid therapeutics to treat this terrible condition,” added Dr. Titus. “A new study led by investigators at the Stanford University School of Medicine has implicated the blocking of endocannabinoids — signaling substances that are the brain’s internal versions of the psychoactive chemicals in marijuana and hashish — in the early pathology of Alzheimer’s disease.”
The article also discusses recent research by the Salk Institute for Biological Studies indicating the apparent effectiveness of cannabinoids and their ability to reduce brain inflammation. This shows the potential benefits of RSHO™ on international patients suffering from diseases and disorders like Parkinson’s disease and forms of epilepsy.
You can view the full story HERE.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system. As of 2015, ANVISA has allowed cannabidiol treatments for any medical condition a doctor sees could help the patient. HempMeds® Brasil has had doctor prescriptions for Epilepsy, Parkinson’s, Alzheimer’s, Cancer, Autism, Multiple Sclerosis and Chronic Pain to date and is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070